A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort

INTRODUCTION: Ruxolitinib has been approved for the treatment of myelofibrosis (MF). In this study, we present safety and efficacy findings from an analysis of 104 patients with intermediate- and high-risk MF in a Brazilian cohort of the JUMP study who received treatment with ruxolitinib. METHODS: J...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares, Renato, Souza, Carmino Antonio De, Paley, Carole, Bouard, Catherine, Tiwari, Ranjan, Pasquini, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031100/
https://www.ncbi.nlm.nih.gov/pubmed/31235325
http://dx.doi.org/10.1016/j.htct.2019.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031100/
https://www.ncbi.nlm.nih.gov/pubmed/31235325
http://dx.doi.org/10.1016/j.htct.2019.01.009

Ejemplares similares